Aardvark Therapeutics Faces Securities Probe Over Trial Halt and FDA Clinical Hold

Pomerantz LLP has launched an investigation into potential securities fraud claims against Aardvark Therapeutics, Inc. ($AARD) following a series of significant regulatory setbacks that have devastated shareholder value. The biotech company voluntarily paused its Phase 3 HERO trial in February 2026 due to cardiac safety concerns, followed by an FDA clinical hold on its lead candidate ARD-101 in May 2026—a sequence of events that triggered a combined stock decline exceeding 75% over just a few months.

The investigation centers on whether company leadership adequately disclosed safety risks and other material information to investors before these developments became public. For a clinical-stage biopharmaceutical company like Aardvark, which typically relies on a single or small pipeline of experimental drugs, regulatory setbacks of this magnitude can be existential threats to the business.

The Timeline of Clinical and Regulatory Setbacks

The troubles began in February 2026 when Aardvark Therapeutics voluntarily halted its Phase 3 HERO trial—a critical late-stage study that would have been essential for eventual FDA approval and market launch of ARD-101. The reason given was cardiac safety concerns that emerged during the trial, a serious red flag in drug development that signals potential cardiovascular toxicity in patients receiving the experimental treatment.

Following this initial pause, the market responded swiftly and decisively. The stock declined 56.2% in the aftermath of the trial halt announcement, representing a massive loss in shareholder value. However, the damage did not stop there. In May 2026, just three months later, the FDA issued a clinical hold on ARD-101—a regulatory action that essentially freezes all clinical testing of the drug until the company can adequately address the agency's safety concerns.

This second blow proved even more severe for shareholders:

• Additional 32.1% stock decline following the FDA clinical hold announcement
• Combined decline of approximately 75.2% over the five-month period
• Dramatic erosion of shareholder value in a compressed timeframe
• Signal that safety issues may be more fundamental than initially disclosed

For investors who held $AARD shares, the sequence of events represented a catastrophic loss. A $100,000 investment made before February 2026 would have been worth approximately $24,800 by June 2026.

Market Context: Biotech Risk and Disclosure Standards

The Aardvark Therapeutics situation reflects broader challenges in the biopharmaceutical sector, where clinical-stage companies operate in an environment of substantial uncertainty. Unlike larger, diversified pharmaceutical companies with multiple revenue-generating products, biotech firms focused on a single drug candidate face existential risk when that candidate encounters problems.

Securities class action investigations by firms like Pomerantz LLP typically examine whether company insiders and management possessed knowledge of safety signals or other material information that was not adequately communicated to public shareholders. Key questions in such investigations generally include:

• Were safety signals visible in interim data before the public announcement?
• Did company statements about trial safety profile match actual data?
• Did executives sell shares or exercise stock options before the announcements?
• Was information withheld from investors who might have traded on that knowledge?

In the biotech sector, where FDA clinical holds and trial pauses can occur relatively frequently, the distinction between standard regulatory developments and potentially fraudulent concealment is crucial. However, a 56% decline on a trial pause followed by an additional 32% decline on an FDA clinical hold suggests the market may have viewed these events as either unexpected or inadequately disclosed in advance.

The regulatory environment for biopharmaceuticals has become increasingly stringent regarding safety disclosures. Companies are expected to maintain robust communication channels with investors about trial progress and emerging safety data. An FDA clinical hold—essentially a regulatory "stop work" order—represents a serious escalation that suggests safety concerns that were not resolved through the voluntary trial pause alone.

Investor Implications: Legal Risk and Business Viability

For current and former shareholders of Aardvark Therapeutics, the Pomerantz LLP investigation opens potential pathways to recover losses through securities litigation if evidence of fraud or material omissions is established. Securities class actions in the biotech space have historically succeeded when companies made optimistic public statements about trial progress or safety profiles that contradicted internal data or communications.

The broader implications extend beyond $AARD to the entire clinical-stage biotech sector:

For investors: The case underscores the extreme concentration risk in single-asset biotech companies. Diversification across multiple pipeline candidates, even if earlier stage, typically provides more insulation from the total loss scenario that Aardvark shareholders experienced.

For company management: The investigation highlights the critical importance of transparent, timely disclosure of adverse trial developments. Regulators and the investing public have little tolerance for companies that appear to withhold or delay disclosure of material safety information.

For the biotech sector: The dramatic stock decline and subsequent legal investigation may prompt other clinical-stage companies to reassess their investor communication practices and ensure rigorous disclosure controls around trial data and safety signals.

The financial impact on Aardvark Therapeutics extends beyond stock price collapse. If ARD-101 cannot be revived—if the cardiac safety concerns prove intractable—the company may have limited options: pivot to developing new drug candidates (expensive and time-consuming), merge with a larger entity, or face eventual insolvency. For a company whose entire valuation was presumably built on the success of ARD-101, an FDA clinical hold is essentially an extinction-level event.

Looking Forward: Regulatory Precedent and Recovery Prospects

The path forward for Aardvark Therapeutics depends on whether the company can identify and address the underlying causes of the cardiac safety concerns. Some FDA clinical holds are eventually lifted after companies submit comprehensive safety data and remediation plans. However, cardiac toxicity in a Phase 3 trial—after the drug has already been extensively studied—is particularly challenging to overcome. It suggests a fundamental property of the drug rather than a dosing or population-specific issue.

For shareholders, both current and former, the Pomerantz LLP investigation represents a potential recovery mechanism, though litigation timelines in securities cases typically span multiple years, and recoveries depend on establishing clear evidence of fraud or material omission. The burden of proof is substantial, and not all class actions succeed.

The Aardvark Therapeutics case will likely serve as a cautionary tale in biotech investing—a reminder that even companies advancing to Phase 3 trials face existential risks, and that transparent communication about emerging safety signals is essential both as a legal matter and as a practical investor protection mechanism. As the biotech sector continues to face regulatory scrutiny and investor skepticism, companies that fail to adequately disclose material information will increasingly face both regulatory consequences and shareholder litigation.